Exact Sciences stock holds steady as Abbott acquisition reshapes growth story
Published on 09/18/2026 at 13:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Exact Sciences stock (ISIN US30063P1057) closed at USD 67.42 on Nasdaq on September 16, 2026, virtually unchanged on the day even as the broader market fell after the latest Federal Reserve rate hike. According to Ad-hoc-news, this resilient performance comes against a backdrop of double-digit revenue growth and a tightened loss profile in the company’s latest quarterly figures.
Second-quarter 2026 figures show improving profitability
In its most recent quarterly report for the second quarter of 2026, Exact Sciences reported revenue of USD 774.0 million, up 12.5 percent from USD 688.0 million in the second quarter of 2025, reflecting continued growth in its core screening and precision oncology businesses. According to Ad-hoc-news, the company posted a net loss of USD 42.0 million for the quarter, an improvement compared with a net loss of USD 68.0 million in the prior-year quarter as operating leverage and cost discipline helped narrow the deficit.
Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached USD 96.0 million in the second quarter of 2026, compared with USD 70.0 million a year earlier, underlining how scale effects are starting to translate into better underlying profitability. As highlighted by Ad-hoc-news, this improvement in EBITDA gives investors a clearer path toward potential break-even and profitability if revenue growth continues at a similar pace.
Full-year 2026 guidance points to mid-teens growth
The second-quarter 2026 report also included guidance for full-year 2026 revenue in a range of USD 3.05 billion to USD 3.15 billion, implying mid-teens percentage growth compared with the USD 2.72 billion recorded in fiscal year 2025. According to Ad-hoc-news, this outlook suggests that the company expects its screening and oncology portfolio to maintain momentum despite a more challenging macro environment.
In addition, the guidance range signals that Exact Sciences could add roughly USD 330 million to USD 430 million in incremental revenue versus fiscal year 2025, depending on where within the range it ultimately lands. As noted by Ad-hoc-news, the combination of mid-teens top-line growth and improving EBITDA provides a key narrative for investors looking at the stock’s long-term potential.
Stock holds firm amid Fed-driven volatility
As of the last completed trading day on September 16, 2026, Exact Sciences stock closed at USD 67.42 on Nasdaq, with an intraday range between USD 66.91 and USD 68.05, underscoring the relatively tight trading band in spite of the broader market volatility following the Federal Reserve’s latest rate increase. According to Ad-hoc-news, the near-flat daily performance contrasts with declines in major indices, suggesting that investors may be focusing more on company-specific fundamentals than on short-term macro noise.
For shareholders, the key takeaway is that the stock’s stability around the USD 67 mark is supported by visible progress in revenue growth, loss reduction and EBITDA expansion rather than by speculative momentum. While detailed 52-week range and market capitalization figures are not highlighted in the recent coverage, the as-of September 16, 2026 closing price offers a clear benchmark for assessing the valuation against the company’s 2026 guidance and the improved second-quarter metrics.
Closing price and investor perspective
Exact Sciences stock thus enters September 18, 2026 with a reference closing price of USD 67.42 on Nasdaq as of September 16, 2026, giving investors a stable base level from which to weigh the company’s mid-teens revenue growth outlook and improving EBITDA trajectory against broader market risks such as higher interest rates and sector competition.
Exact Sciences stock - key data
- Company: Exact Sciences Corporation
- ISIN: US30063P1057
- Ticker: EXAS
- Trading venue: Nasdaq
- Price (as of September 16, 2026): 67.42 USD
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500
